BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33563892)

  • 1. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
    Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
    Shen P; Jing Y; Zhang R; Cai MC; Ma P; Chen H; Zhuang G
    Oncogene; 2018 May; 37(22):3039-3044. PubMed ID: 29535424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
    Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
    J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
    Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
    Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
    Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
    Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
    Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
    Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis.
    Xu S; Moss TJ; Laura Rubin M; Ning J; Eterovic K; Yu H; Jia R; Fan X; Tetzlaff MT; Esmaeli B
    Mod Pathol; 2020 Jul; 33(7):1256-1263. PubMed ID: 31937901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
    Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
    Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
    Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
    Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
    Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.
    Li M; Zhang Z; Li X; Ye J; Wu X; Tan Z; Liu C; Shen B; Wang XA; Wu W; Zhou D; Zhang D; Wang T; Liu B; Qu K; Ding Q; Weng H; Ding Q; Mu J; Shu Y; Bao R; Cao Y; Chen P; Liu T; Jiang L; Hu Y; Dong P; Gu J; Lu W; Shi W; Lu J; Gong W; Tang Z; Zhang Y; Wang X; Chin YE; Weng X; Zhang H; Tang W; Zheng Y; He L; Wang H; Liu Y; Liu Y
    Nat Genet; 2014 Aug; 46(8):872-6. PubMed ID: 24997986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic
    Li M; Liu F; Zhang F; Zhou W; Jiang X; Yang Y; Qu K; Wang Y; Ma Q; Wang T; Bai L; Wang Z; Song X; Zhu Y; Yuan R; Gao Y; Liu Y; Jin Y; Li H; Xiang S; Ye Y; Zhang Y; Jiang L; Hu Y; Hao Y; Lu W; Chen S; Gu J; Zhou J; Gong W; Zhang Y; Wang X; Liu X; Liu C; Liu H; Liu Y; Liu Y
    Gut; 2019 Jun; 68(6):1024-1033. PubMed ID: 29954840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-genome sequencing reveals the mutational landscape of metastatic small-cell gallbladder neuroendocrine carcinoma (GB-SCNEC).
    Li M; Liu F; Zhang Y; Wu X; Wu W; Wang XA; Zhao S; Liu S; Liang H; Zhang F; Ma Q; Xiang S; Li H; Jiang L; Hu Y; Gong W; Zhang Y; Ma T; Zhang K; Liu Y; Liu Y
    Cancer Lett; 2017 Apr; 391():20-27. PubMed ID: 28040546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
    Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
    J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes.
    Nepal C; Zhu B; O'Rourke CJ; Bhatt DK; Lee D; Song L; Wang D; Van Dyke AL; Choo-Wosoba H; Liu Z; Hildesheim A; Goldstein AM; Dean M; LaFuente-Barquero J; Lawrence S; Mutreja K; Olanich ME; Lorenzo Bermejo J; ; Ferreccio C; Roa JC; Rashid A; Hsing AW; Gao YT; Chanock SJ; Araya JC; Andersen JB; Koshiol J
    J Hepatol; 2021 May; 74(5):1132-1144. PubMed ID: 33276026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UV Signature Mutations Reclassify Salivary High-grade Neuroendocrine Carcinomas as Occult Metastatic Cutaneous Merkel Cell Carcinomas.
    Sun L; Cliften PF; Duncavage EJ; Lewis JS; Chernock RD
    Am J Surg Pathol; 2019 May; 43(5):682-687. PubMed ID: 30986802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
    Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
    Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.